Free product worth Rs 499 on all myUpchar products
Supime 500/250 Injection is a commercial drug that is prescribed in the form of Injection. The alternative uses of Supime 500/250 Injection have also been explained below.
Medical history of the patient along with age and gender determines the dosage of Supime 500/250 Injection. The condition it has been prescribed for, and the route of administration also determine the right dosage. This information has been provided in detail in the dosage section.
Apart from the aforementioned side effects, Supime 500/250 Injection can also lead to other problems, which have been listed below. These side effects of Supime 500/250 Injection are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
Supime 500/250 Injection's effect during pregnancy is Safe and Safe while nursing. In addition, Supime 500/250 Injection's effects on the liver, heart and kidney are discussed below in the Supime 500/250 Injection related warnings section.
Supime 500/250 Injection can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Supime 500/250 Injection in conditions like Kidney Disease, Kidney Disease, Jaundice. The section on Supime 500/250 Injection contraindications lists all such conditions.
Drug interactions for Supime 500/250 Injection have been reported in the medical literature. Refer to the list below for further details.
In addition to the above precautions for Supime 500/250 Injection, it is important to know that it is not safe while driving, and is not habit-forming.
Supime 500/250 Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Is the use of Supime 500/250 Injection safe for pregnant women?
There are no side effects of Supime in pregnant women.
Is the use of Supime 500/250 Injection safe during breastfeeding?
Supime does not show any harmful effects in lactating women.
What is the effect of Supime 500/250 Injection on the Kidneys?
Supime rarely affects the kidneys.
What is the effect of Supime 500/250 Injection on the Liver?
Supime is not harmful for the liver.
What is the effect of Supime 500/250 Injection on the Heart?
You can take Supime without any fear of damage to the heart.
If you are suffering from any of the following diseases, you should not take Supime 500/250 Injection unless your doctor advises you to do so -
Is this Supime 500/250 Injection habit forming or addictive?
No, there is no any evidence that Supime 500/250 Injection is addictive.
Interaction between Food and Supime 500/250 Injection
Eating certain foods may increase the time it takes Supime 500/250 Injection to have an effect. You should consult your doctor about it.
Interaction between Alcohol and Supime 500/250 Injection
Due to lack of research, there is no information about the side effects of taking Supime 500/250 Injection with alcohol.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 291-292
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 729
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Maxipime™ (Cefepime Hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; UNASYN® (ampicillin sodium/sulbactam sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 725
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 160-162
